DelveInsight’s, “Nasal Polyposis - Pipeline Insight, 2022,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Nasal Polyposis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Nasal Polyposis: Overview
A nasal polyp (also called nasal polyposis) is a benign (noncancerous) tumor that grows from the lining of the nose or sinuses. These polyps usually occur in both the right and left nasal passages and obstruct the flow of air. They can make your nose feel stuffy, and can decrease your sense of smell. Not all growths in the nose are polyps. Nasal polyps may result from chronic (long-lasting) inflammation of the lining of the nose, although they often occur for no apparent reason. People with chronic hay fever (allergic rhinitis) are more likely than others to develop nasal polyps. In addition, nasal polyps commonly develop in children with cystic fibrosis.
"Nasal Polyposis - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Nasal Polyposis pipeline landscape is provided which includes the disease overview and Nasal Polyposis treatment guidelines. The assessment part of the report embraces, in depth Nasal Polyposis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Nasal Polyposis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Nasal Polyposis R&D. The therapies under development are focused on novel approaches to treat/improve Nasal Polyposis.
This segment of the Nasal Polyposis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Nasal Polyposis Emerging Drugs
Benralizumab: AstraZeneca
Benralizumab is a monoclonal antibody that attracts natural killer cells via antibody-dependent cellular cytotoxicity activity (ADCC activity) to induce direct and rapid depletion of eosinophils in the blood and in the airway. The drug is in phase 3 of clinical trials for the treatment of severe nasal polyposis.
AK001: Allakos
AK001 is a therapeutic antibody that targets a receptor present on eosinophils and mast cells. Binding of antibody to this receptor causes inhibition of mast cell activity and selective depletion of activated eosinophils. AK001's action is highly specific to mast cells and eosinophils and has potential to be of benefit in a wide spectrum of conditions where these cells are involved. It is currently in phase 2 of clinical trial for the treatment of nasal polyposis.
Further product details are provided in the report……..
This segment of the report provides insights about the different Nasal Polyposis drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 4+ key companies which are developing the therapies for Nasal Polyposis. The companies which have their Nasal Polyposis drug candidates in the most advanced stage, i.e. phase III include AstraZeneca.
DelveInsight’s report covers around 4+ products under different phases of clinical development like
Nasal Polyposis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Nasal Polyposis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nasal Polyposis drugs.
Current Treatment Scenario and Emerging Therapies:
Introduction
Executive Summary
Nasal Polyposis: Overview
Pipeline Therapeutics
Therapeutic Assessment
Nasal Polyposis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Nasal Polyposis Collaboration Deals
late Stage Products (Phase III)
Benralizumab: AstraZeneca
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
AK001: Allakos
Drug profiles in the detailed report…..
Inactive Products
Nasal Polyposis Key Companies
Nasal Polyposis Key Products
Nasal Polyposis- Unmet Needs
Nasal Polyposis- Market Drivers and Barriers
Nasal Polyposis- Future Perspectives and Conclusion
Nasal Polyposis Analyst Views
Nasal Polyposis Key Companies
Appendix
List of Table
Table 1: Total Products for Nasal Polyposis
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for Nasal Polyposis
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• AstraZeneca.
• Allakos
• Idorsia Pharmaceuticals
• Novartis
